TY - JOUR AU - Ameri, Pietro AU - Mercurio, Valentina AU - Pollesello, Piero AU - Anker, Markus S. AU - Backs, Johannes AU - Bayes‐Genis, Antoni AU - Borlaug, Barry A. AU - Burkhoff, Daniel AU - Caravita, Sergio AU - Chan, Stephen Y. AU - de Man, Frances AU - Giannakoulas, George AU - González, Aránzazu AU - Guazzi, Marco AU - Hassoun, Paul M. AU - Hemnes, Anna R. AU - Maack, Cristoph AU - Madden, Brendan AU - Melenovsky, Vojtech AU - Müller, Oliver J. AU - Papp, Zoltán AU - Pullamsetti, Soni Savai AU - Rainer, Peter P. AU - Redfield, Margaret M. AU - Rich, Stuart AU - Schiattarella, Gabriele G. AU - Skaara, Hall AU - Stellos, Kostantinos AU - Tedford, Ryan J. AU - Thum, Thomas AU - Vachiery, Jean Luc AU - van der Meer, Peter AU - Van Linthout, Sophie AU - Pruszczyk, Piotr AU - Seferovic, Petar AU - Coats, Andrew J.S. AU - Metra, Marco AU - Rosano, Giuseppe AU - Rosenkranz, Stephan AU - Tocchetti, Carlo Gabriele TI - A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association ( HFA ) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function JF - EUROPEAN JOURNAL OF HEART FAILURE J2 - EUR J HEART FAIL PY - 2024 SN - 1388-9842 DO - 10.1002/ejhf.3236 UR - https://m2.mtmt.hu/api/publication/34827495 ID - 34827495 AB - Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH‐LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH‐LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH‐LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre‐clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early‐stage development of candidate therapies for PH‐LHF. LA - English DB - MTMT ER - TY - JOUR AU - Abdisa, Kenbon Beyene AU - Némethné Szerdahelyi, Emőke AU - Molnár, Máté András AU - Friedrich, László AU - Lakner, Zoltán AU - Koris, András AU - Tóth, Attila AU - Nath, Arijit TI - Metabolic Syndrome and Biotherapeutic Activity of Dairy (Cow and Buffalo) Milk Proteins and Peptides: Fast Food-Induced Obesity Perspective—A Narrative Review JF - BIOMOLECULES J2 - BIOMOLECULES VL - 14 PY - 2024 IS - 4 SP - 478 SN - 2218-273X DO - 10.3390/biom14040478 UR - https://m2.mtmt.hu/api/publication/34820678 ID - 34820678 AB - Metabolic syndrome (MS) is defined by the outcome of interconnected metabolic factors that directly increase the prevalence of obesity and other metabolic diseases. Currently, obesity is considered one of the most relevant topics of discussion because an epidemic heave of the incidence of obesity in both developing and underdeveloped countries has been reached. According to the World Obesity Atlas 2023 report, 38% of the world population are presently either obese or overweight. One of the causes of obesity is an imbalance of energy intake and energy expenditure, where nutritional imbalance due to consumption of high-calorie fast foods play a pivotal role. The dynamic interactions among different risk factors of obesity are highly complex; however, the underpinnings of hyperglycemia and dyslipidemia for obesity incidence are recognized. Fast foods, primarily composed of soluble carbohydrates, non-nutritive artificial sweeteners, saturated fats, and complexes of macronutrients (protein-carbohydrate, starch-lipid, starch-lipid-protein) provide high metabolic calories. Several experimental studies have pointed out that dairy proteins and peptides may modulate the activities of risk factors of obesity. To justify the results precisely, peptides from dairy milk proteins were synthesized under in vitro conditions and their contributions to biomarkers of obesity were assessed. Comprehensive information about the impact of proteins and peptides from dairy milks on fast food-induced obesity is presented in this narrative review article. LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Eszter Lilla AU - Orbán-Kálmándi, Rita Angéla AU - Bagoly, Zsuzsa AU - Lóczi, Linda AU - Deli, Tamás AU - Török, Olga AU - Molnár, Sarolta AU - Baráth, Sándor AU - Singh, Parvind AU - Hevessy Zsuzsanna, Dóra AU - Katona, Éva AU - Fagyas, Miklós AU - Szabó, Attila Ádám AU - Molnár, Szabolcs AU - Krasznai, Zoárd Tibor TI - Case report: Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 15 PY - 2024 SP - 1 SN - 1664-3224 DO - 10.3389/fimmu.2024.1329236 UR - https://m2.mtmt.hu/api/publication/34719971 ID - 34719971 LA - English DB - MTMT ER - TY - JOUR AU - Bäck, Magnus AU - von Haehling, Stephan AU - Papp, Zoltán AU - Piepoli, Massimo F. TI - Editors' highlight picks from 2023 in ESC heart failure JF - ESC HEART FAILURE J2 - ESC HEART FAIL PY - 2024 SN - 2055-5822 DO - 10.1002/ehf2.14727 UR - https://m2.mtmt.hu/api/publication/34689913 ID - 34689913 AB - Heart failure is a devastating syndrome affecting an increasingly high number of patients worldwide. Its aetiology and pathogenesis are complex with the involvement of factors ranging from the genetic material through valvular dysfunctions to numerous organs beyond the entire cardiovascular system. Based on continuous efforts of the heart failure scientific community we have witnessed major advances in many related disciplines during the last year. For example, epidemiological aspects—paving the road for improved risk prevention—have been thoroughly analysed for various geographical regions. Additionally, evidence‐based approaches now allow the introduction of novel guideline recommended medical therapies (i.e. sodium‐glucose transporter 2 inhibitors, and iron supplementation) while basic and translational research aim to explore additional molecular targets for future heart failure diagnostics and medications. All above aspects are addressed in this article, where a selection of articles published in the ESC Heart Failure journal in 2023 are highlighted. The editors are confident that the scientific contributions of ESC Heart Failure effectively served a highly relevant area of cardiovascular research last year. LA - English DB - MTMT ER - TY - JOUR AU - Sütő, Renáta AU - Pócsi, Marianna AU - Fagyas, Miklós AU - Kalina, Edit AU - Fejes, Zsolt AU - Szentkereszty, Zoltán AU - Kappelmayer, János AU - Nagy, Béla TI - Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection JF - MICROORGANISMS J2 - MICROORGANISMS VL - 12 PY - 2024 IS - 1 SP - 229 SN - 2076-2607 DO - 10.3390/microorganisms12010229 UR - https://m2.mtmt.hu/api/publication/34528941 ID - 34528941 AB - Severe SARS-CoV-2 elicits a hyper-inflammatory response that results in intravascular inflammation with endothelial injury, which contributes to increased mortality in COVID-19. To predict the outcome of severe SARS-CoV-2 infection, we analyzed the baseline level of different biomarkers of vascular disorders in COVID-19 subjects upon intensive care unit (ICU) admission and prior to any vaccination. A total of 70 severe COVID-19 patients (37 survivors and 33 non-survivors) were included with 16 age- and sex-matched controls. Vascular dysfunction was monitored via soluble VCAM-1, E-selectin, ACE2 and Lp-PLA2, while abnormal platelet activation was evaluated by soluble P-selectin and CD40L in parallel. These results were correlated with routine laboratory parameters and disease outcomes. Among these parameters, VCAM-1 and ACE2 showed significantly higher serum levels in COVID-19 patients with early death vs. convalescent subjects. VCAM-1 was significantly correlated with the Horowitz index (r = 0.3115) and IL-6 (r = 0.4599), while ACE2 was related to E-selectin (r = 0.4143) and CD40L (r = 0.2948). Lp-PLA2 was altered in none of these COVID-19 subcohorts and showed no relationship with the other parameters. Finally, the pre-treatment level of VCAM-1 (≥1420 ng/mL) and ACE2 activity (≥45.2 μU/mL) predicted a larger risk for mortality (Log-Rank p = 0.0031 and p = 0.0117, respectively). Vascular dysfunction with endothelial cell activation is linked to lethal COVID-19, and highly elevated soluble VCAM-1 and ACE2 at admission to ICU may predict unfavorable outcomes. LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Attila Ádám AU - Enyedi, Enikő Edit AU - Altorjay, István AU - Hajnal, Péter AU - Pintér, Tamás Bence AU - Mányiné Siket, Ivetta AU - Váradi, Csongor AU - Bányai, Emese AU - Tóth, Attila AU - Papp, Zoltán AU - Fagyas, Miklós TI - Get reliable laboratory findings – how to recognize the deceptive effects of angiotensin-converting enzyme inhibitor therapy in the laboratory diagnostics of sarcoidosis? JF - CLINICAL CHEMISTRY AND LABORATORY MEDICINE J2 - CLIN CHEM LAB MED PY - 2024 SN - 1434-6621 DO - 10.1515/cclm-2023-1288 UR - https://m2.mtmt.hu/api/publication/34496858 ID - 34496858 AB - Objectives Serum angiotensin-converting enzyme (ACE) is the only biomarker routinely used in the laboratory diagnostics of sarcoidosis, and ACE inhibitor (ACEi) drugs are among the most prescribed drugs worldwide. Taking ACEi can mislead medical teams by lowering ACE activity, delaying diagnosis and giving a false impression of disease activity of sarcoidosis. We aimed to develop a simple method to detect the presence of ACEi drugs in samples, to investigate the ACEi medication-caused interference and consequences in a retrospective study. Methods ACE activity and the level of ACE inhibition were determined for 1823 patients with suspected sarcoidosis. These values were compared with the therapeutic information at the first and follow-up visits. Results A total of 302 patients had biochemical evidence of an ACEi drug effect during diagnostic ACE activity testing. In their case, ACE activity was significantly lower (median(IQR): 4.41 U/L(2.93–6.72)) than in patients not taking ACEi (11.32 U/L(8.79–13.92), p<0.01). In 62 sarcoidosis patients, the ACEi reduced ACE activity to the reference range or below. Only in 40 % of the cases was the medication list recorded in the outpatient chart and only in 3 cases was low ACE activity associated with ACEi use. 67 % of the repeated ACE activity measurements were also performed during ACEi therapy. Conclusions Our study revealed that the use of ACEi is common in patients with suspected sarcoidosis. The ACE activity lowering effect of ACEi drugs may escape the attention of medical teams which can lead to diagnostic errors and unnecessary tests. Nevertheless, these pitfalls can be avoided by using a method suggested by our team. LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Emese AU - Fagyas, Miklós AU - Nagy, Béla AU - Siket, Ivetta Mányiné AU - Szőke, Blanka AU - Mártha, Lilla AU - Mahdi, Mohamed AU - Erdősi, Gábor AU - Pólik, Zsófia AU - Kappelmayer, János AU - Papp, Zoltán AU - Borbély, Attila AU - Szabó, Tamás AU - Balla, József AU - Balla, György AU - Bácsi, Attila AU - Szekanecz, Zoltán AU - Bay, Péter AU - Tóth, Attila TI - Distinct subsets of anti-pulmonary autoantibodies correlate with disease severity and survival in severe COVID-19 patients JF - GEROSCIENCE: OFFICIAL JOURNAL OF THE AMERICAN AGING ASSOCIATION (AGE) J2 - GEROSCIENCE VL - 46 PY - 2024 IS - 2 SP - 1561 EP - 1574 PG - 14 SN - 2509-2715 DO - 10.1007/s11357-023-00887-2 UR - https://m2.mtmt.hu/api/publication/34148390 ID - 34148390 AB - Autoantibodies targeting the lung tissue were identified in severe COVID-19 patients in this retrospective study. Fifty-three percent of 104 patients developed anti-pulmonary antibodies, the majority of which were IgM class, suggesting that they developed upon infection with SARS-CoV-2. Anti-pulmonary antibodies correlated with worse pulmonary function and a higher risk of multiorgan failure that was further aggravated if 3 or more autoantibody clones were simultaneously present (multi-producers). Multi-producer patients were older than the patients with less or no autoantibodies. One of the identified autoantibodies (targeting a pulmonary protein of ~ 50 kDa) associated with worse clinical outcomes, including mortality. In summary, severe COVID-19 is associated with the development of lung-specific autoantibodies, which may worsen the clinical outcome. Tissue proteome-wide tests, such as the ones applied here, can be used to detect autoimmunity in the post-COVID state to identify the cause of symptoms and to reveal a new target for treatment. LA - English DB - MTMT ER - TY - JOUR AU - Poelzl, G. AU - Altenberger, J. AU - Comin-Colet, J. AU - Delgado, J. F. AU - Fedele, F. AU - Carcia-Gonzales, M. J. AU - Gustafsson, F. AU - Masip, J. AU - Papp, Zoltán AU - Stoerk, S. AU - Ulmer, H. AU - Maier, S. AU - Vrtovec, B. AU - Wikstroem, G. AU - Zima, E. AU - Bauer, A. TI - Repetitive LevosimenDan infusionS for patients with advanced chronic heart failure in the vulnerable post-discharge period: The multinational randomized LeoDOR trial JF - WIENER KLINISCHE WOCHENSCHRIFT: MIDDLE EUROPEAN JOURNAL OF MEDICINE J2 - WIEN KLIN WOCHENSCHR VL - 135 PY - 2023 IS - S2 SP - S345 EP - S346 SN - 0043-5325 UR - https://m2.mtmt.hu/api/publication/34768455 ID - 34768455 LA - English DB - MTMT ER - TY - JOUR AU - Polzl, G. AU - Altenberger, J. AU - Comin-Colet, J. AU - Delgado, J. AU - Fedele, F. AU - Garcia-Gonzales, M. J. AU - Gustafsson, F. AU - Masip, J. AU - Papp, Zoltán AU - Stoerk, S. AU - Ulmer, H. AU - Vrtovec, B. AU - Wikstrom, G. AU - Zima, E. AU - Bauer, A. TI - Repetitive LevosimenDan infusions fOR patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial JF - EUROPEAN HEART JOURNAL J2 - EUR HEART J VL - 44 PY - 2023 IS - Supplement_2 SP - - PG - 1 SN - 0195-668X UR - https://m2.mtmt.hu/api/publication/34722686 ID - 34722686 LA - English DB - MTMT ER - TY - JOUR AU - Ladanyi, Z. AU - Ruppert, M. AU - Fábián, Alexandra AU - Ujvari, A. AU - Bódi, Beáta AU - Papp, Zoltán AU - Radovits, T. AU - Sayour, A. A. AU - Molnar, L. AU - Straub, E. AU - Nagy, A. AU - Kovacs, A. AU - Lakatos, B. K. AU - Merkely, B. TI - Myocardial work index and myofilament calcium sensitivity: possible hand in hand markers of contractility in aortic valve stenosis patients - a translational study JF - EUROPEAN HEART JOURNAL J2 - EUR HEART J VL - 44 PY - 2023 IS - Supplement 2 PG - 2 SN - 0195-668X DO - 10.1093/eurheartj/ehad655.011 UR - https://m2.mtmt.hu/api/publication/34689842 ID - 34689842 LA - English DB - MTMT ER -